Recent advances in treatment of lupus erythematosus and antiphospholipid syndrome;Lupus et syndrome des antiphospholipides : actualités thérapeutiques

Reanimation

Volumn 15, Issue 4, 2006, Pages 245-252

  Godeau, B ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Antiphospholipid syndrome; Mycophenolate mofetil; Rituximab; Systemic lupus erythematosus; Thrombosis

Indexed keywords

ABATACEPT; ANTICOAGULANT AGENT; AZATHIOPRINE; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HUMAN; LUPUS ERYTHEMATOSUS; SHORT SURVEY; THROMBOSIS;

EID: 33747877621     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2006.07.007     Document Type: Short Survey

References (22)

1. Godeau B. Syndrome des antiphospholipides. Hématologie 12 (2006) 1-10
2. Mok C.C., Lau C.S., and Wong R.W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophophamide therapy. Arthritis Rheum. 41 (1998) 831-837
3. Chan T.M., Li F.K., Tang C.S., Wong R.W., Fang G.X., Ji Y.L., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N. Engl. J. Med. 343 (2000) 1156-1162
4. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350 (2004) 971-980
5. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. N. Engl. J. Med. 353 (2005) 2219-2228
6. Sibilia J., and Sordet C. Immunothérapie du lupus systémique : innovations et perspectives. Rev. Rhum. 72 (2005) 572-591
7. Sibilia J. Sordet. Le rituximab : une biothérapie originale dans les maladies auto-immunes. Rev. Med. Interne 26 (2005) 485-500
8. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2572-2581
9. Thatayatikom A., and White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun. Rev. 5 (2006) 18-24
10. Marriette X. The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases. Joint Bone Spine 71 (2004) 357-360
11. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352 (2005) 2598-2608
12. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
13. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354 (2006) 924-933
14. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42 (1999) 1309-1311
15. e édition (2004), Flammarion, Paris 148-154
16. Ruiz-Irastorza G., Egurbide M.V., Ugalde J., and Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch. Intern. Med. 164 (2004) 77-82
17. Crowther M.A., and Wisloff F. Evidence based treatment of the antiphospholipid syndrome. II. Optimal anticoagulant therapy for thrombosis. Thromb. Res. 115 (2005) 3-8
18. Crowther M.A., Ginsberg J.S., Julian J., Denburg J., Hirsh J., Douketis J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 349 (2003) 1133-1138
19. Finazzi G., Marchioli R., Brancaccio V., Schinco P., Wisloff F., Musial J., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 3 (2005) 848-853
20. Asherson R.A., Cervera R., Piette J.C., Font J., Lie J.T., Burcoglu A., et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine 77 (1998) 195-207
21. Amoura Z., Costedoat-Chalumeau N., Veyradier A., Wolf M., Ghillani-Dalbin P., Cacoub P., et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum. 50 (2004) 3260-3264
22. Erkan D., Cervera R., and Asherson R.A. Catastrophic antiphospholipid syndrome. Arthritis Rheum. 48 (2003) 3320-3327